Mumbai, New York, February 02, 2026: Global pharma major Lupin Limited (Lupin) today announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer.

Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs, and supply chain to ensure global access to Telacebec.

“This collaboration with TB Alliance underscores Lupin’s enduring commitment to improving patient outcomes in areas of significant unmet medical need,” said Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin. “By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”

“Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected,” said Mel Spigelman, MD, President and CEO, TB Alliance. “By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.”

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit www.lupin.com or follow us on LinkedIn  https://www.linkedin.com/company/lupin

About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB and adjacent mycobacterial diseases such as leprosy and Buruli ulcer. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Cystic Fibrosis Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR) through KfW, Global Disease Eradication Fund (South Korea), Global Health Innovative Technology Fund, Korea International Cooperation Agency, MedAccess, Raoul Follerau Foundation, South Korea’s Ministry of Foreign Affairs, United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP), United States Department of State, United States National Institutes for Health – National Center for Advancing Translational Sciences (NCATS), United States National Institutes for Health – National Institute of Allergy and Infectious Diseases (NIAID), and Unitaid. For more information, please visit: www.tballiance.org.

For further information or queries, please contact:

Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com